Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oral Hypoglycemic Agents

Oral Hypoglycemic Agents of carbutamide (l-butyl-3-p-aminobenzene sulfony­ lurea) (BZ-55; Invenol, Nadisan) into clinical use in Germany in 1955 (1, 2) quickly aroused widespread interest in oral hypoglycemic agents. This led to an extraordinary amount of activity throughout the world both in research laboratories and in clinics, resulting in a huge volume of publications during the past five years. Because of the difficulty soon encountered in elucidating was turned anew to the nature of the underlying defect in diabetes and the certain agents were given clinical trial with large numbers of patients. Fol­ the mode and site of action of the oral agents, the attention of investigators m�thod and place of action of insulin, still-not well understood. In succession, lowing closely on the heels of carbutamide came tolbutamide (l-butyl-3-p­ toluene sulfonylurea) (D860; Orinase, Artosin, Dolipol, Rastinon). Then chlorpropamide (1-propyl-3-p-chlorobenzene sulfonylurea) (Diabinese), and later metahexamide (WP 40) (1-cyclohexyl-3-[m-amino-p-methylbenzene sulfonylurea]), were introduced. In addition to these closely related aryl­ tients. Of the biguanides, the ones used most extensively have been phen­ formin (phenethylbiguanide) (W32; DB!) and butyl-biguanide (W37; DBV). In almost unprecedented number and frequency from 1956 until the fall of 1959, symposia were held at which laboratory workers and clinicians pre­ sented data http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Medicine Annual Reviews

Oral Hypoglycemic Agents

Marble, A
Annual Review of Medicine , Volume 12 (1) – Feb 1, 1961
Download PDF
16 pages

Loading next page...
 
/lp/annual-reviews/oral-hypoglycemic-agents-iNMdCehgaA

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Annual Reviews
Copyright
Copyright 1961 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0066-4219
eISSN
1545-326X
DOI
10.1146/annurev.me.12.020161.001031
pmid
13766421
Publisher site
See Article on Publisher Site

Abstract

of carbutamide (l-butyl-3-p-aminobenzene sulfony­ lurea) (BZ-55; Invenol, Nadisan) into clinical use in Germany in 1955 (1, 2) quickly aroused widespread interest in oral hypoglycemic agents. This led to an extraordinary amount of activity throughout the world both in research laboratories and in clinics, resulting in a huge volume of publications during the past five years. Because of the difficulty soon encountered in elucidating was turned anew to the nature of the underlying defect in diabetes and the certain agents were given clinical trial with large numbers of patients. Fol­ the mode and site of action of the oral agents, the attention of investigators m�thod and place of action of insulin, still-not well understood. In succession, lowing closely on the heels of carbutamide came tolbutamide (l-butyl-3-p­ toluene sulfonylurea) (D860; Orinase, Artosin, Dolipol, Rastinon). Then chlorpropamide (1-propyl-3-p-chlorobenzene sulfonylurea) (Diabinese), and later metahexamide (WP 40) (1-cyclohexyl-3-[m-amino-p-methylbenzene sulfonylurea]), were introduced. In addition to these closely related aryl­ tients. Of the biguanides, the ones used most extensively have been phen­ formin (phenethylbiguanide) (W32; DB!) and butyl-biguanide (W37; DBV). In almost unprecedented number and frequency from 1956 until the fall of 1959, symposia were held at which laboratory workers and clinicians pre­ sented data

Journal

Annual Review of Medicine – Annual Reviews

Published: Feb 1, 1961

There are no references for this article.